Literature DB >> 29445252

Implications of Measurement Assay Type in Design of HIV Experiments.

LaMont Cannon1, Aditya Jagarapu1, Cesar A Vargas-Garcia2, Michael J Piovoso2, Ryan Zurakowski1,2.   

Abstract

Time series measurements of circular viral episome (2-LTR) concentrations enable indirect quantification of persistent low-level Human Immunodeficiency Virus (HIV) replication in patients on Integrase-Inhibitor intensified Combined Antiretroviral Therapy (cART). In order to determine the magnitude of these low level infection events, blood has to be drawn from a patients at a frequency and volume that is strictly regulated by the Institutional Review Board (IRB). Once the blood is drawn, the 2-LTR concentration is determined by quantifying the amount of HIV DNA present in the sample via a PCR (Polymerase Chain Reaction) assay. Real time quantitative Polymerase Chain Reaction (qPCR) is a widely used method of performing PCR; however, a newer droplet digital Polymerase Chain Reaction (ddPCR) method has been shown to provide more accurate quantification of DNA. Using a validated model of HIV viral replication, this paper demonstrates the importance of considering DNA quantification assay type when optimizing experiment design conditions. Experiments are optimized using a Genetic Algorithm (GA) to locate a family of suboptimal sample schedules which yield the highest fitness. Fitness is defined as the expected information gained in the experiment, measured by the Kullback-Leibler Divergence (KLD) between the prior and posterior distributions of the model parameters. We compare the information content of the optimized schedules to uniform schedules as well as two clinical schedules implemented by researchers at UCSF and the University of Melbourne. This work shows that there is a significantly greater gain information in experiments using a ddPCR assay vs. a qPCR assay and that certain experiment design considerations should be taken when using either assay.

Entities:  

Year:  2018        PMID: 29445252      PMCID: PMC5809129          DOI: 10.1109/CDC.2017.8264262

Source DB:  PubMed          Journal:  Proc IEEE Conf Decis Control        ISSN: 0743-1546


  18 in total

1.  Relationship between pre-existing viral reservoirs and the re-emergence of plasma viremia after discontinuation of highly active anti-retroviral therapy.

Authors:  T W Chun; R T Davey; M Ostrowski; J Shawn Justement; D Engel; J I Mullins; A S Fauci
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

2.  Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression.

Authors:  H Hatano; S Vogel; C Yoder; J A Metcalf; R Dewar; R T Davey; M A Polis
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

3.  Re-emergence of HIV after stopping therapy.

Authors:  T W Chun; R T Davey; D Engel; H C Lane; A S Fauci
Journal:  Nature       Date:  1999-10-28       Impact factor: 49.962

4.  Modeling uncertainty in single-copy assays for HIV.

Authors:  Rutao Luo; Michael J Piovoso; Ryan Zurakowski
Journal:  J Clin Microbiol       Date:  2012-07-25       Impact factor: 5.948

5.  Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies.

Authors:  Claire Vandergeeten; Rémi Fromentin; Esther Merlini; Mariam B Lawani; Sandrina DaFonseca; Wendy Bakeman; Amanda McNulty; Moti Ramgopal; Nelson Michael; Jerome H Kim; Jintanat Ananworanich; Nicolas Chomont
Journal:  J Virol       Date:  2014-08-13       Impact factor: 5.103

6.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

Authors:  Maria J Buzón; Marta Massanella; Josep M Llibre; Anna Esteve; Viktor Dahl; Maria C Puertas; Josep M Gatell; Pere Domingo; Roger Paredes; Mark Sharkey; Sarah Palmer; Mario Stevenson; Bonaventura Clotet; Julià Blanco; Javier Martinez-Picado
Journal:  Nat Med       Date:  2010-03-14       Impact factor: 53.440

7.  Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.

Authors:  J K Wong; M Hezareh; H F Günthard; D V Havlir; C C Ignacio; C A Spina; D D Richman
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

8.  Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial.

Authors:  Hiroyu Hatano; Matthew C Strain; Rebecca Scherzer; Peter Bacchetti; Deborah Wentworth; Rebecca Hoh; Jeffrey N Martin; Joseph M McCune; James D Neaton; Russell P Tracy; Priscilla Y Hsue; Douglas D Richman; Steven G Deeks
Journal:  J Infect Dis       Date:  2013-08-23       Impact factor: 5.226

9.  HIV model parameter estimates from interruption trial data including drug efficacy and reservoir dynamics.

Authors:  Rutao Luo; Michael J Piovoso; Javier Martinez-Picado; Ryan Zurakowski
Journal:  PLoS One       Date:  2012-07-16       Impact factor: 3.240

10.  ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.

Authors:  Frank Maldarelli; Sarah Palmer; Martin S King; Ann Wiegand; Michael A Polis; JoAnn Mican; Joseph A Kovacs; Richard T Davey; Diane Rock-Kress; Robin Dewar; Shuying Liu; Julia A Metcalf; Catherine Rehm; Scott C Brun; George J Hanna; Dale J Kempf; John M Coffin; John W Mellors
Journal:  PLoS Pathog       Date:  2007-04       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.